View in EDS PDF Full Text

Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide.

Saved in:
Bibliographic Details
Title: Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide.
Authors: Singer M (AUTHOR), Coluzzi F (AUTHOR), O'Brien A (AUTHOR), Clapp LH (AUTHOR), Singer, Mervyn (AUTHOR), Coluzzi, Flaminia (AUTHOR), O'Brien, Alastair (AUTHOR), Clapp, Lucie H (AUTHOR)
Source: Lancet. 5/28/2005, Vol. 365 Issue 9474, p1873-1875. 3p.
Abstract: We describe three critically ill patients who received drugs with K(ATP) channel-opening properties and subsequently developed severe life-threatening complications, including hyperkalaemia and cardiovascular disturbances. Administration of the sulfonylurea-receptor inhibitor glibenclamide promptly reversed these abnormalities. Over the past 3 years, we have seen this syndrome and response in five patients taking nicorandil, ciclosporin, or isoflurane, which suggests that this disorder arises more frequently than is currently realised. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 106537778
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Singer+M%22">Singer M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Coluzzi+F%22">Coluzzi F</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22O'Brien+A%22">O'Brien A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Clapp+LH%22">Clapp LH</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Singer%2C+Mervyn%22">Singer, Mervyn</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Coluzzi%2C+Flaminia%22">Coluzzi, Flaminia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22O'Brien%2C+Alastair%22">O'Brien, Alastair</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Clapp%2C+Lucie+H%22">Clapp, Lucie H</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 5/28/2005, Vol. 365 Issue 9474, p1873-1875. 3p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: We describe three critically ill patients who received drugs with K(ATP) channel-opening properties and subsequently developed severe life-threatening complications, including hyperkalaemia and cardiovascular disturbances. Administration of the sulfonylurea-receptor inhibitor glibenclamide promptly reversed these abnormalities. Over the past 3 years, we have seen this syndrome and response in five patients taking nicorandil, ciclosporin, or isoflurane, which suggests that this disorder arises more frequently than is currently realised. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=106537778
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/s0140-6736(05)66619-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 3
        StartPage: 1873
    Titles:
      – TitleFull: Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Singer M
      – PersonEntity:
          Name:
            NameFull: Coluzzi F
      – PersonEntity:
          Name:
            NameFull: O'Brien A
      – PersonEntity:
          Name:
            NameFull: Clapp LH
      – PersonEntity:
          Name:
            NameFull: Singer, Mervyn
      – PersonEntity:
          Name:
            NameFull: Coluzzi, Flaminia
      – PersonEntity:
          Name:
            NameFull: O'Brien, Alastair
      – PersonEntity:
          Name:
            NameFull: Clapp, Lucie H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 05
              Text: 5/28/2005
              Type: published
              Y: 2005
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 365
            – Type: issue
              Value: 9474
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1